European drug regulatory agency recommends approval of Dupixen for the treatment of patients with chronic obstructive pulmonary disease
我放心你带套猛
发表于 2024-5-31 15:51:00
211
0
0
On May 31st local time, Sanofi and Regenerative announced that the European Medicines Agency's Committee on Medicines for Human Use (CHMP) has adopted a positive opinion recommending the approval of Dupixent (Duprizumab) in the treatment of adult patients with chronic obstructive pulmonary disease (COPD) in the European Union. Two Phase 3 trials have shown that Dupixent can significantly reduce acute exacerbation of COPD and improve lung function. It is expected that the European Commission will announce its final decision on the Dupixent application in the coming months.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Jike An Intelligent: Actively promoting the localization production plan in Europe
- Eisai/Bojian Alzheimer's disease drug rejected by the European Union, and Eli Lilly monoclonal antibody may be affected
- AstraZeneca's market value has surpassed £ 200 billion for the first time! The bold bet on anti-cancer drugs is yielding results
- TSMC's 12 inch factory in Europe will start construction
- Bristol Myers Squibb's original tumor treatment drug Abraxane has been officially launched in China
- Viking Cruises announces 2025 European river cruise routes: covering 11 countries and 42 destinations in Europe
- European privacy regulators investigate Google's use of data for artificial intelligence models
- Delivery of over 30000 units in a single month for two consecutive months, officially launched in Europe. Zhu Jiangming: Received 11 orders with soft hands
- European investment giant JAB acquires 86 million shares of JDE Peet's held by Mondelez International
- BeiGene BeiZeAn receives positive feedback from the European Medicines Agency's Committee for Medicinal Products for Human Use
-
【英偉達の需要が高すぎる?SKハイニックス:黄仁勲がHBM 4チップの6カ月前納入を要求!】SKハイニックスの崔泰源(チェ・テウォン)会長は月曜日、インビダーの黄仁勲(ファン・インフン)CEOが同社の次世代高帯域 ...
- 琳271
- 前天 17:54
- 支持
- 反对
- 回复
- 收藏
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;(TALZENNA®,一般名:トルエンスルホン酸タラゾールパーリカプセル)は2024年10月29日に国家薬品監督管理局(NMPA)の承認を得て、HRR遺伝子突然変異 ...
- 什么大师特
- 昨天 17:41
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...
- Dubssgshbsbdhd
- 昨天 16:27
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた:作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...
- 波大老师
- 昨天 14:41
- 支持
- 反对
- 回复
- 收藏